{
    "clinical_study": {
        "@rank": "92609", 
        "arm_group": [
            {
                "arm_group_label": "Arm A: Targeted Therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Personalized treatment, targeted therapy against the alteration based on molecular profiling."
            }, 
            {
                "arm_group_label": "Arm B: Standard-of-Care Therapy", 
                "arm_group_type": "Experimental", 
                "description": "Standard-of-Care treatment not selected on basis of alteration analysis."
            }
        ], 
        "brief_summary": {
            "textblock": "The goal of this research study is to compare the effects of treatment based on molecular\n      profiling to those of the standard-of-care.\n\n      Treatment Assignment:\n\n      From a tumor biopsy, a molecular profile of the disease is established.  Based on genetic\n      profiling, the following interventions will follow:\n\n      A) If there is no abnormality, patients will be treated according to the patient's doctor as\n      to what is in their best interest.\n\n      B) If there is an abnormality and there is an FDA-approved drug for the tumor type, patients\n      will be offered that treatment.\n\n      C) If there is an abnormality and there is no FDA-approved drug for the abnormality and the\n      tumor type, patients will be randomly assigned to Arm A (targeted therapy) or Arm B\n      (standard-of-care therapy)."
        }, 
        "brief_title": "IMPACT 2: Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer", 
        "condition": "Metastatic Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasm Metastasis", 
                "Neoplasms", 
                "Neoplasms, Second Primary"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients whose tumors progress on protocol-assigned treatment will have achieved the primary\n      study endpoint and have the option of crossing over to the other treatment arm.  Imaging\n      studies will be repeated every 2 cycles after initiation of treatment in both randomized\n      arms."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients must have pathologically confirmed metastatic cancer.\n\n          2. Patients must have received 0-3 prior therapies.\n\n          3. For patients with melanoma: biologics, cytokines, or cell therapies do not count as\n             prior therapies.\n\n          4. The patient has measurable disease.\n\n          5. The patient has Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n\n          6. The patient has biopsy-accessible tumor. For patients who had no prior anticancer\n             therapy and had surgical resection within a year and tumor tissue is immediately\n             available, that tumor will be analyzed and no biopsy will be needed.\n\n          7. The patient has normal organ and marrow function, defined as absolute neutrophil\n             count>/= 1,000/\u00b5l; platelets >/=100,000/\u00b5l (unless these abnormalities are due to\n             bone marrow involvement).\n\n          8. The patient has adequate hepatic function as defined by a total bilirubin level</=1.5\n             x the upper limit of normal (ULN), unless the patient has known Gilbert's disease,\n             and alanine aminotransferase (ALT)/ serum glutamic pyruvic transaminase levels (SGPT)\n             </= 2.5 * ULN (unless the patient has liver metastases).\n\n          9. The patient has serum creatinine clearance >/= 50 ml/min by the Cockcroft-Gault\n             formula.\n\n         10. If the patient has brain metastasis, they must have been stable (treated and/or\n             asymptomatic) and the patient must have been off steroids for at least 2 weeks.\n\n         11. The patient is >/=18 years of age.\n\n         12. The patient has provided signed informed consent.\n\n         13. The patient has had no previously treated malignancy, other than the patient's known\n             cancer.\n\n         14. Patients with a history of basal cell carcinoma of the skin or pre-invasive carcinoma\n             of the cervix are eligible.\n\n         15. Women of childbearing potential must agree to use adequate contraception (hormonal or\n             barrier method of birth control; abstinence) prior to study entry and for the\n             duration of study participation. Childbearing potential will be defined as women who\n             have had menses within the past 12 months and who have not had a tubal ligation,\n             hysterectomy, or bilateral oophorectomy. Should a woman become pregnant or suspect\n             that she is pregnant while participating in this study, she should inform her\n             treating physician immediately.\n\n         16. Male subjects must agree to use effective contraception or abstinence while on study\n             and for 90 days after last dose of study drug.\n\n        Exclusion Criteria:\n\n          1. Patients who are randomized to the control arm must not receive therapy based on\n             prior molecular profiling.\n\n          2. The patient has received chemotherapy, surgery, or radiotherapy within 3 weeks of\n             initiating study treatment (4 weeks for bevacizumab or investigational drugs) or the\n             patient has not recovered (grade \u22652 from side effects of the previous therapy).\n\n          3. Patients for whom an FDA-approved therapy for the tumor type and the molecular\n             alteration is available will be excluded from the randomization.\n\n          4. The patient has cardiac conditions as follows: uncontrolled hypertension (BP >\n             140/90) despite optimal therapy, uncontrolled angina, ventricular arrhythmias,\n             congestive heart failure (New York Heart Association Class II or above), baseline\n             left ventricular ejection fraction (LVEF) </= 50%, prior or current cardiomyopathy,\n             atrial fibrillation with heart rate >100 bpm, unstable ischaemic heart disease (MI\n             within 6 months prior to starting treatment or angina requiring use of nitrates more\n             than once weekly).\n\n          5. The patient has peripheral neuropathy >/= grade 2.\n\n          6. The patient is pregnant (confirmed by serum b-human chorionic gonadotropin (HCG), if\n             applicable) or is breastfeeding.\n\n          7. The patient has concurrent severe and/or uncontrolled medical disease that could\n             compromise participation in the study (i.e., uncontrolled diabetes, severe infection\n             requiring active treatment, severe malnutrition, chronic severe liver or renal\n             disease).\n\n          8. The patient has refractory nausea and vomiting or chronic gastrointestinal diseases\n             (e.g., inflammatory bowel disease) or has had significant bowel resection that would\n             preclude adequate absorption (for oral therapy only).\n\n          9. The patient is unable to swallow capsules and/or has a surgical or anatomical\n             condition that precludes swallowing and absorbing oral medication on an ongoing basis\n             (for oral therapy only)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1362", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02152254", 
            "org_study_id": "PA12-1161"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A: Targeted Therapy", 
                "description": "Patients randomized to receive targeted therapy will participate in clinical trials, and will be treated at the expansion phase of Phase I clinical trials or in Phase II clinical trials. If a clinical trial is not available and a commercially available targeted therapy exists (FDA-approved for another indication),  patients may receive the FDA-approved drug.", 
                "intervention_name": "Targeted Therapy Based on Molecular Profiling", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm B: Standard-of-Care Therapy", 
                "description": "Standard-of-care treatment regimen will be left to the discretion of the treating physician.", 
                "intervention_name": "Standard-of-Care Therapy", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Metastatic Cancer", 
            "Molecular Profiling", 
            "Genomic alteration analysis of the tumor", 
            "Advanced Cancer Therapy", 
            "Gene mutations", 
            "Tumor biopsy", 
            "Personalized medicine"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "link": {
            "description": "University of Texas  MD Anderson Cancer Center Website", 
            "url": "http://www.mdanderson.org"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "University of Texas MD Anderson Cancer Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer: Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT 2)", 
        "overall_contact": {
            "last_name": "Apostolia M. Tsimberidou, MD, PHD", 
            "phone": "713-792-4259"
        }, 
        "overall_contact_backup": {
            "last_name": "Adoneca H. Fortier", 
            "phone": "713-563-9458"
        }, 
        "overall_official": {
            "affiliation": "M.D. Anderson Cancer Center", 
            "last_name": "Apostolia M. Tsimberidou, MD, PHD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Progression-free survival (PFS) of patients treated with a targeted therapy selected on the basis of mutational analysis of the tumor compared with PFS of those whose treatment is not selected based on alteration analysis.", 
            "measure": "Comparison of Progression-Free Survival (PFS) Between the Two Randomized Arms", 
            "safety_issue": "No", 
            "time_frame": "Continuous Monitoring, expected range from 2 months to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02152254"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "M.D. Anderson Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Foundation Medicine", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "M.D. Anderson Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}